Koninklijke Philips N.V.

PHG • Medical - Devices

$26.00

— 0.00 (0.00%)

Current price

EarningsLatest report: Mar 31, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$25.14B

Growth

-0.2%

Cash Flow

4/5

Trend

Mostly stable

Evidence

Positive free cash flow · 0.93Consistent free cash flow · 4/5Manageable debt level · 0.74Healthy liquidity · 1.32Negative growth trend

Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 6, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$26.00

Change0.00%

Shares Out968.53M

Market Cap$25.14B

52W Range21.95 - 33.44

Beta0.92

P/E37.22

P/S5.76

P/B1.97

P/FCF192.33

EV/Sales7.19

EV/EBITDA52.17

Price$26.00

Change0.00%

Shares Out968.53M

Market Cap$25.14B

52W Range21.95 - 33.44

Beta0.92

P/E37.22

P/S5.76

P/B1.97

P/FCF192.33

EV/Sales7.19

EV/EBITDA52.17

EV/FCF240.11

Earnings Yield2.69%

FCF Yield0.52%

Dividend Yield0.00%

Gross Margin45.18%

Oper. Margin7.98%

Profit Margin5.02%

Debt/Eq0.74

Current Ratio1.32

Quick Ratio0.94

Revenue 5Y-0.21%

Volume894.74K

Avg Volume1.07M

EPS Surprise0.03

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

45/100

Financial Strength

Debt, cash, stability

65/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

75/100

Why this score▼

Positive free cash flow · 0.93Consistent free cash flow · 4/5Manageable debt level · 0.74Healthy liquidity · 1.32Negative growth trend

Analyst view

Analyst sentiment and price target

PHG

Analyst sentiment

Based on 22 analyst votes · 2026-10-20

68/100

Neutral

Bullish

Hold

Bearish

Company Overview

IPO: 3/17/1980

Industry: Medical - Devices

P/B i: 1.97

Debt / Equity i: 0.74

Operating Margin: 7.98%

Net Margin: 5.02%

ROE i: -

ROIC: -

Financial Health

Score13 / 20

Debt / Equity: 0.74

Current Ratio: 1.32

Quick Ratio: 0.94

Status: Good

🧾

No insider activity

No recent insider transactions available.

About the Company

Koninklijke Philips N.V.

Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

Source - link

Peers

BNTX DXCM LH MTD NTRA PODD SNN STE TEVA ZBH

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Philips highlights Integrated Diagnostics' role in the future of cardiovascular informatics following MediReport acquisition

October 20, 2026 Advanced reporting and workflow capabilities developed by MediReport are expected to complement Philips' cardiovascular informatics portfolio and support its evolution toward a more connected, AI-enabled and cloud-ready cardiovascular experience. Amsterdam, the Netherlands – October 20, 2026 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today highlighted how advanced reporting and workflow capabilities developed by MediReport are expected to complement its cardiovascular informatics portfolio and support its broader Integrated Diagnostics vision ahead of Transcatheter Cardiovascular Therapeutics (TCT) 2026.

GlobeNewsWire

Philips: A Risky Turnaround Worth A 'Strong Buy' Upgrade

I am upgrading Philips (PHG) to "Strong Buy," citing undervaluation and improving fundamentals despite ongoing risks. PHG's turnaround is supported by renewed comparable sales growth, margin improvement in Connected Care and Personal Health, and operational progress offsetting cost inflation. Quality issues and Chinese market pressures continue to weigh on margins and order intake, making recovery uneven and execution risk concentrated in Q4.

Seeking Alpha

EXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe

October 15, 2026 Five-year research project unites 42 public and private partners across 17 countries to conduct 22 clinical studies involving 14,000+ patients; first patients will be enrolled this month Project aims to help cardiac patients avoid deterioration through early, personalized interventions delivered across the cardiac care journey Interventions will be co-created with patients and designed to systematically address socioeconomic, sex- and gender-related and digital access gaps With a total budget of EUR 27.6 million, the project is co-funded by the European Union Innovative Health Initiative (IHI) and industry partners Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the five-year EXIT-CVD research project, co-funded by the European Union Innovative Health Initiative (IHI) and the industry partners. The research consortium is led by University Medical Center Groningen (UMCG) and Philips, and aims to transform how cardiovascular disease is detected, monitored and treated.

GlobeNewsWire

Philips Oral Healthcare Establishes Global Clinical Advisory Board to Help Shape the Future of Oral Care Through Scientific and Clinical Insight

AMSTERDAM--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in oral healthcare, today announced the formation of the Philips Sonicare Global Clinical Advisory Board, a group of external oral healthcare experts established to help shape the future of Philips Oral Healthcare through science, clinical insight and meaningful innovation. The board brings together 12 international experts with complementary expertise across clinical practice, research, education, behavior change.

Business Wire

Koninklijke Philips N.V. (NYSE:PHG) Given Average Rating of “Hold” by Brokerages

Shares of Koninklijke Philips N.V. (NYSE: PHG - Get Free Report) have earned a consensus recommendation of "Hold" from the five brokerages that are covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a hold recommendation. Several research analysts recently weighed in on the stock. Zacks Research raised shares of Koninklijke Philips

Defense World

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-06	0.24	0.27	0.03
2026-02-10	0.565	0.7	0.135
2025-11-04	0.37	0.37	0
2025-07-29	0.3174	0.41	0.0926
2025-05-06	0.14	0.27	0.13
2025-02-19	0.55	0.54	-0.01
2024-10-28	0.35	0.35	0
2024-07-29	0.25	0.32	0.07
2024-04-29	0.26	0.28	0.02
2024-01-29	0.41	0.44	0.03
2023-10-23	0.18	0.36	0.18
2023-07-24	0.23	0.31	0.08